MedTrace Logo

Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)

NCT01169935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-02-05

No results posted yet for this study

Summary

Treatment of a wide range of diseases using stem cells and other types of cell appears promising. Following administration of cells it is often not clear where exactly the cells have gone and how many of them have reached the target site. This has been one of the challenges of developing these treatment options further. We have developed a method of labelling human cells with a magnetic resonance imaging (MRI) "contrast agent" which contains tiny iron filings. Following intravenous administration it is possible to see where the iron-labelled cells have gone using MRI scanning. We would like to do is to demonstrate that these cells behave normally and migrate to a site of inflammation. We plan to induce an area of inflammation in the forearm of healthy volunteers using the Mantoux test (a test of immunity against tuberculosis) before giving the labelled cells intravenously. After the Mantoux test we will give these volunteers iron-labelled cells and do MRI scans of their forearm to determine whether these cells can be seen accumulating in the target site.

Conditions

  • Healthy

Interventions

DRUG

Administration of intra-dermal Endorem

single dose, intradermal

BIOLOGICAL

Mantoux test

single dose, intradermal

BIOLOGICAL

Autologous Endorem-labelled mononuclear cells

single dose, intravenous

DRUG

Administration of Endorem

single dose, intravenous

Sponsors & Collaborators

  • Translational Medicine Research Collaboration

    collaborator OTHER

  • British Heart Foundation

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Jenny M Richards, MBChB MRCS · University of Edinburgh

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01169935 on ClinicalTrials.gov